Pneumagen Ltd Demonstrates Preclinical Proof-of-Concept in Oncology for Neumonco, a Novel Carbohydrate Binding Module

ST ANDREWS, Scotland, Oct. 15, 2019 /PRNewswire/ -- Pneumagen Ltd, focused on treating infectious disease and oncology by targeting the human glycome, today announced promising in vivo data in oncology from a novel Carbohydrate Binding Module (mCBM) generated from its proprietary GlycoTarge platform.